Faeth Therapeutics, Inc. Financials
SNSE
All currency values in $ millions unless otherwise noted
Scroll
| Income Statement | DEC 2025 | DEC 2024 | DEC 2023 | DEC 2022 | DEC 2021 |
|---|---|---|---|---|---|
| General & Administrative | $11 | $13 | $19 | $20 | $16 |
| Total Operating Expenses | $22 | $33 | $37 | $50 | $37 |
| Operating Income | -$22 | -$33 | -$37 | -$50 | -$37 |
| Non-Operating | |||||
| Net Interest Expense | $1 | $2 | $3 | $2 | $0 |
| Other Non-Operating Income (Expense) | -$0 | -$0 | -$0 | $0 | -$0 |
| EBT (Earnings Before Tax) | -$21 | -$30 | – | – | – |
| Income Tax Expense | $0 | $0 | – | – | – |
| Net Income | |||||
| Net Income | -$21 | -$30 | -$34 | -$49 | -$37 |
| EPS (Basic) | -$16.72 | -$24.01 | -$24.40 | -$31.60 | -$26.60 |
| EPS (Diluted) | -$16.72 | -$24.01 | -$24.40 | -$31.60 | -$26.60 |
| Weighted Avg Shares (Basic) | 1.3M | 25.1M | 28.0M | 30.7M | 27.7M |
| Weighted Avg Shares (Diluted) | 1.3M | 25.1M | 28.0M | 30.7M | 27.7M |
| Shares Outstanding | 1.3M | 1.3M | 1.4M | 1.5M | 1.4M |
Faeth Therapeutics (SNSE) financials: revenue, profit and margins
Faeth Therapeutics (SNSE) generated about n/a in revenue and -$211 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.
Frequently asked
Is Faeth Therapeutics profitable?+
Faeth Therapeutics reported about -$211 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
SourceFinancial statements computed from the 10-Q filed 30 Oct 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 4 Nov 2026. How this is calculated.
Fiscal year ends Dec.
Peers
Pharmaceutical Preparations · Pick stocks to compare with SNSE
Held by ETFs
SNSE is in 2 US ETFs. The largest of them, with SNSE's weight in each:
Spot a number that looks wrong? Check it in SNSE's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing SNSE
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.